Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

One of the goals of the Insurance Institute for Business and Home Safety is to make homes and commercial buildings stronger.

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

A study published this week in the peer-reviewed journal Scientific Reports examined the long-term impacts of having shingles ...